Seagen and Zai Lab ink partnership on Tivdak expansion into China and surrounding areas; NC biotech snaps up seed funding
Zai Lab has signed on to commercialize Seagen and Genmab’s Tivdak — an ADC for recurrent or metastatic cervical cancer in patients in which chemotherapy isn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.